Organic Letters
Letter
Scheme 6. Gram-Scale Preparation and Further Synthetic
Applications
ACKNOWLEDGMENTS
■
We thank the National Natural Science Foundation of China
(21572154, 21772181 and 21776148) and NSFC−Shandong
Joint Fund for Marine Science Research Centers (U1606403)
for financial support. Financial support from the Natural
Science Foundation of Shandong Province (ZR2016BM07)
and the Fundamental Research Funds for the Central
Universities (201612013) is also gratefully acknowledged.
REFERENCES
■
(1) (a) Courant, T.; Dagousset, G.; Masson, G. Synthesis 2015, 47,
1799−1826. (b) Dehli, J. R.; Legros, J.; Bolm, C. Chem. Commun.
2005, 973−986. (c) Yet, L. Chem. Rev. 2003, 103, 4283−4306.
(d) Lenz, G. R. Synthesis 1978, 1978, 489−518. (e) Matsubara, R.;
Kobayashi, S. Acc. Chem. Res. 2008, 41, 292−301. (f) Kuranaga, T.;
Sesoko, Y.; Inoue, M. Nat. Prod. Rep. 2014, 31, 514−532.
(g) Tschesche, R.; Last, H.; Fehlhaber, H. W. Chem. Ber. 1967,
100, 3937−3943. (h) Okamoto, K.; Sakagami, M.; Feng, F.; Togame,
H.; Takemoto, H.; Ichikawa, S.; Matsuda, A. Org. Lett. 2011, 13,
5240−5243. (i) Gopalaiah, K.; Kagan, H. B. Chem. Rev. 2011, 111,
4599−4657.
Scheme 7. Proposed Mechanism
(2) (a) Dekker, K. A.; Aiello, R. J.; Hirai, H.; Inagaki, T.; Sakakibara,
T.; Suzuki, Y.; Thompson, J. F.; Yamauchi, Y.; Kojima, N. J. Antibiot.
configured α-haloenamides. The high stereoselectivity might
be attributed to the steric repulsion shown in the transition
state, which blocks halogen anion from approaching the
keteniminium intermediate from the R1 side.
In summary, the synthetically versatile (E)-α-halo products
were provided directly via hydrohalogenation of ynamides,
thioalkynes, ynol ethers, etc., using aqueous hydrogen halides.
This method features wide substrate scope, high functional
group tolerance, mild conditions, high efficiency, rapid
transformation, and high stereoselectivity. In addition, (Z)-
configured α-haloenamides were readily produced via visible-
light-promoted (E)- to (Z)-isomerization, and the synthetic
elaboration of the resultant products further verified the
usefulness of this protocol.
̈
1998, 51, 14−20. (b) Kunze, B.; Jansen, R.; Sasse, F.; Hofle, G.;
Reichenbach, H. J. Antibiot. 1998, 51, 1075−1080. (c) Shen, R.;
Porco, J. A. Org. Lett. 2000, 2, 1333−1336.
(3) (a) Meier, S.; Wurthwein, E. U. Chem. Ber. 1990, 123, 2339−
̈
2343. (b) Baran, P. S.; Shenvi, R. A.; Mitsos, C. A. Angew. Chem., Int.
Ed. 2005, 44, 3714−3717. (c) Galli, C.; Rappoport, Z. Acc. Chem. Res.
̀
2003, 36, 580−587. (d) Miniere, S.; Cintrat, J. C. Synthesis 2001,
2001, 0705−0707.
(4) (a) Endo, N.; Iwasawa, T. Tetrahedron 2017, 73, 5833−5840.
(b) Fujino, D.; Yorimitsu, H.; Osuka, A. J. Am. Chem. Soc. 2014, 136,
6255−6258. (c) Flynn, A. B.; Ogilvie, W. W. Chem. Rev. 2007, 107,
4698−4745. (d) Lemay, A. B.; Vulic, K. S.; Ogilvie, W. W. J. Org.
Chem. 2006, 71, 3615−3618. (e) Lander, P. A.; Hegedus, L. S. J. Am.
Chem. Soc. 1994, 116, 8126−8132. (f) Stille, V. J. K. Angew. Chem.
1986, 98, 504−519. (g) Du, Y. F.; Liu, R. H.; Linn, G.; Zhao, K. Org.
Lett. 2006, 8, 5919−5922.
ASSOCIATED CONTENT
* Supporting Information
■
(5) (a) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem.
Soc. Rev. 2008, 37, 320−330. (b) Li, H. Q.; Lv, P. C.; Yan, T.; Zhu, H.
L. Anti-Cancer Agents Med. Chem. 2009, 9, 471−480. (c) Volz, N.;
Clayden, J. Angew. Chem., Int. Ed. 2011, 50, 12148−12155.
(6) (a) Chelucci, G. Chem. Rev. 2012, 112, 1344−1462. (b) Coutrot,
P.; Laurenco, C.; Petrova, J.; Savignac, P. Synthesis 1976, 1976, 107−
108. (c) Sacasa, P. R.; Zayas, J.; Wnuk, S. F. Tetrahedron Lett. 2009,
50, 5424−5427.
(7) (a) Perri, S. T.; Moore, H. W. J. Am. Chem. Soc. 1990, 112,
1897−1905. (b) Corey, E. J.; Beames, D. J. J. Am. Chem. Soc. 1972,
94, 7210−7211. (c) Stille, J. K.; Groh, B. L. J. Am. Chem. Soc. 1987,
109, 813−817. (d) Kazankova, M. A.; Chirkov, E. A.; Kochetkov, A.
N.; Efimova, I. V.; Beletskaya, I. P. Tetrahedron Lett. 1999, 40, 573−
576. (e) Yu, W. S.; Jin, Z. D. J. Am. Chem. Soc. 2001, 123, 3369−3370.
(f) Yu, W. S.; Jin, Z. D. J. Am. Chem. Soc. 2002, 124, 6576−6583.
(8) Mulder, J. A.; Kurtz, K. C. M.; Hsung, R. P.; Coverdale, H.;
Frederick, M. O.; Shen, L. C.; Zificsak, C. Org. Lett. 2003, 5, 1547−
1550.
(9) (a) Sato, A. H.; Ohashi, K.; Iwasawa, T. Tetrahedron Lett. 2013,
54, 1309−1311. (b) Ohashi, K.; Mihara, S.; Sato, A. H.; Ide, M.;
Iwasawa, T. Tetrahedron Lett. 2014, 55, 632−635. (c) Ide, M.;
Ohashi, K.; Mihara, S.; Iwasawa, T. Tetrahedron Lett. 2014, 55, 2130−
2133.
(10) Maity, P.; Klos, M. R.; Kazmaier, U. Org. Lett. 2013, 15, 6246−
6249.
(11) Prabagar, B.; Nayak, S.; Mallick, R. K.; Prasad, R.; Sahoo, A. K.
Org. Chem. Front. 2016, 3, 110−115.
(12) Kim, S. W.; Um, T.-W.; Shin, S. Chem. Commun. 2017, 53,
2733−2736.
S
The Supporting Information is available free of charge on the
Experimental procedures and NMR spectra and
characterizations for all new compounds (PDF)
Accession Codes
CCDC 1844569 contains the supplementary crystallographic
data for this paper. These data can be obtained free of charge
bridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK; fax: +44 1223 336033.
AUTHOR INFORMATION
■
Corresponding Author
ORCID
Author Contributions
∥W.C. and P.C. contributed equally.
Notes
The authors declare no competing financial interest.
D
Org. Lett. XXXX, XXX, XXX−XXX